Highest-materiality recent filing
Cigna Q1 adj EPS $7.79 beats $6.74 YoY; raises FY2026 outlook to at least $30.35/share
GAAP EPS $6.26 vs $4.85 YoY; adjusted EPS $7.79 vs $6.74; revenues $68.5B +5%.
Cigna appoints Brian Evanko as CEO; David Cordani to become Executive Chair
Brian Evanko succeeds David Cordani as CEO effective July 1, 2026; Cordani becomes Executive Chair.
Cigna Q4 adj EPS $8.08 beats; FY adj EPS $29.84; dividend raised; 2026 guide at least $30.25
FY 2025 adjusted income from operations $8.0B ($29.84/share), +4% vs $7.7B ($27.33) in 2024.
Cigna Q3 revenue up 10% to $69.7B, adjusted EPS $7.83, reaffirms FY2025 guidance
Revenue $69.7B (+10% YoY); GAAP net income $1.9B ($6.98 EPS) vs $0.7B ($2.63) in Q3 2024.
Cigna issues $4.5B senior notes across four tranches, uses proceeds to repay term loan
Issued $4.5B senior notes in four tranches: $1B 4.500% due 2030, $1.25B 4.875% due 2032, $1.5B 5.250% due 2036, $750M 6.000% due 2056.
Cigna Q2 2025 adj. EPS $7.20 beats prior year; revenue $67.2B; reaffirms FY adj. EPS $29.60+
Shareholders' net income of $1.5B ($5.71 diluted EPS); adjusted income from operations $1.9B ($7.20 per share), up 7% YoY.
Total revenues $65.5B, up 14% YoY; adjusted EPS $6.74 vs $6.47 prior year.
Cigna upsizes revolving credit facility to $6.5B; CIO Eder resigns
New $6.5B revolving credit and letter of credit facility replaces prior $5.0B agreement.
Cigna finalizes severance agreement with departing EVP Eric Palmer; $10M total value
Eric Palmer's employment ends April 26, 2025; severance includes $5.2M cash and ~$4.8M in equity value.
Cigna completes sale of Medicare businesses to HCSC; proceeds for buybacks
Sale closed March 19, 2025; includes Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies.
Cigna Q4 adj ops income down 8% on stop loss costs; 2025 EPS guidance at least $29.50; dividend +8%
Q4 adjusted income from operations $1.8B ($6.64/sh), down from $2.0B ($6.79/sh) YoY; revenue $65.6B (+28%).
Cigna Q3 adj. EPS $7.51 beats $6.77 YoY; revenue up 30%; reaffirms FY24 outlook
Adjusted income from operations $2.1B ($7.51/share) vs $2.0B ($6.77/share) in Q3 2023; net income includes $1.0B non-cash VillageMD loss.
Cigna Q2 revenue $60.5B (+25% YoY); adj. EPS $6.72 beats $6.13 prior year
Total Q2 revenue $60.5B, +25% YoY; adjusted income from ops $1.9B, +5% YoY.
Cigna posts Q1 GAAP net loss $0.97/share on VillageMD impairment; adj EPS $6.47, outlook raised
Shareholders' net loss $277M ($0.97 loss per share) includes $1.8B non-cash impairment of VillageMD equity securities.
Long-term average annual adjusted EPS growth target raised to 10%-14% from prior target.
Cigna announces $3.2B accelerated share repurchase; initial delivery of ~7.6M shares
Entered ASR agreements with Deutsche Bank and Bank of America to repurchase $3.2B of common stock.
Cigna issues $4.5B in senior notes across four tranches to fund tender offers and refinancing
Issued $1.0B 5.000% notes due 2029, $750M 5.125% notes due 2031, $1.25B 5.250% notes due 2034, $1.5B 5.600% notes due 2054.
Issued $1B 5.000% notes due 2029, $750M 5.125% due 2031, $1.25B 5.250% due 2034, and $1.5B 5.600% due 2054.
Full year 2023 total revenues were $195.3 billion, up 8% year-over-year.
Cigna sells Medicare businesses to HCSC for $3.7B; expects Q1 2025 close, accretive to adjusted EPS
Total transaction value ~$3.7B; includes Medicare Advantage, Supplemental Benefits, Part D, and CareAllies.
Cigna reorganizes: Evanko adds Cigna Healthcare CEO role; Palmer gains enterprise strategy
Brian Evanko becomes President/CEO of Cigna Healthcare effective Feb 5, retains CFO role.
Cigna increases share repurchase authorization by $10B to $11.3B; plans $5B buyback by H1 2024
Board approved $10B increase to share repurchase authorization; total authority now $11.3B.
Cigna Q3 adj EPS $6.77, revenue $49.0B; raises FY2023 adj EPS outlook to at least $24.75
Q3 shareholders' net income $1.4B ($4.74/share) vs $2.8B ($8.97) a year ago; adjusted income from ops $2.0B ($6.77/share) up 8% YoY.
Cigna Q2 adjusted EPS $6.13, revenue up 7% to $48.6B; raises FY revenue guidance
Adjusted income from operations $1.82B ($6.13/share) vs $1.97B ($6.20) YoY, reflecting absence of divested businesses.
Cigna Q1 EPS $5.41 (adj.) on $46.5B revenue; raises FY adj. EPS outlook to at least $24.70
Shareholders' net income $1.3B ($4.24 GAAP EPS); adjusted income from ops $1.6B ($5.41), down from $1.9B in Q1 2022 primarily from divested businesses.
On May 30, 2025, the board of directors (the “Board”) of The Cigna Group (the “Company”) appointed Michael J. Hennigan as an independent member of the Board, effective June 2, 2025.
On April 22, 2025, Ms. Noelle Eder, Executive Vice President, Global Chief Information Officer, The Cigna Group, resigned from the Company to pursue another opportunity, effective May 16, 2025.
On March 13, 2025, The Cigna Group (the “Company”) filed a Form 8-K disclosing that the employment of Eric P. Palmer, Executive Vice President for Enterprise Strategy, The Cigna Group and President and Chief Executive Officer, Evernorth Health Services, will end April 26, 2025.
Among these changes, effective March 31, 2025, Brian C. Evanko will serve as President and Chief Operating Officer, The Cigna Group
Ann M. Dennison will serve as Executive Vice President, Chief Financial Officer, The Cigna Group
The employment of Eric P. Palmer, Executive Vice President for Enterprise Strategy, The Cigna Group and President and Chief Executive Officer, Evernorth Health Services, will end April 26, 2025.
On June 14, 2024, The Cigna Group (the “Company” or “our”) appointed Jamie Kates as the Company’s Chief Accounting Officer, serving as the Company’s principal accounting officer, effective July 1, 2024.
Mary Agoglia Hoeltzel, Senior Vice President and Chief Accounting Officer, notified The Cigna Group of her intention to retire, effective July 1, 2024.
Brian C. Evanko will serve as President and Chief Executive Officer, Cigna Healthcare, in addition to his current role as Executive Vice President and Chief Financial Officer, The Cigna Group.
Eric P. Palmer, currently President and Chief Executive Officer, Evernorth Health Services, will also assume responsibility for enterprise strategy and corporate development in the additional role of the Company’s Executive Vice President for Enterprise Strategy.
Ms. Eder, Executive Vice President, Technology and Operations, now leads the new Technology and Operations function
Ms. Jones, Executive Vice President, Chief Administrative Officer and General Counsel, now also has responsibility for the Human Resources function
Max materiality 0.90 · Median 0.57 · Most common event earnings